Aytu BioPharma Past Earnings Performance
Past criteria checks 0/6
Aytu BioPharma's earnings have been declining at an average annual rate of -44.8%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 58% per year.
Key information
-44.8%
Earnings growth rate
73.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 58.0% |
| Return on equity | -170.6% |
| Net Margin | -74.0% |
| Last Earnings Update | 31 Dec 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Aytu BioPharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 22 | 106 | -78 | 71 | 11 |
| 30 Sep 22 | 102 | -83 | 70 | 14 |
| 30 Jun 22 | 97 | -110 | 70 | 14 |
| 31 Mar 22 | 93 | -111 | 73 | 16 |
| 31 Dec 21 | 82 | -84 | 68 | 11 |
| 30 Sep 21 | 74 | -82 | 62 | 7 |
| 30 Jun 21 | 66 | -58 | 56 | 6 |
| 31 Mar 21 | 57 | -42 | 47 | 2 |
| 31 Dec 20 | 52 | -22 | 42 | 2 |
| 30 Sep 20 | 40 | -13 | 37 | 2 |
| 30 Jun 20 | 28 | -14 | 31 | 2 |
| 31 Mar 20 | 14 | -25 | 24 | 0 |
| 31 Dec 19 | 9 | -24 | 22 | 0 |
| 30 Sep 19 | 7 | -29 | 21 | 1 |
| 30 Jun 19 | 7 | -27 | 19 | 1 |
| 31 Mar 19 | 7 | -12 | 18 | 1 |
| 31 Dec 18 | 5 | -10 | 18 | 1 |
| 30 Sep 18 | 4 | -9 | 17 | 0 |
| 30 Jun 18 | 4 | -10 | 18 | 0 |
| 31 Mar 18 | 4 | -17 | 17 | 0 |
| 31 Dec 17 | 4 | -20 | 17 | 1 |
| 30 Sep 17 | 4 | -21 | 16 | 1 |
| 30 Jun 17 | 3 | -23 | 17 | 1 |
| 31 Mar 17 | 3 | -31 | 17 | 4 |
| 31 Dec 16 | 3 | -33 | 15 | 5 |
| 30 Sep 16 | 3 | -32 | 13 | 6 |
| 30 Jun 16 | 3 | -28 | 9 | 6 |
Quality Earnings: AY20 is currently unprofitable.
Growing Profit Margin: AY20 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AY20 is unprofitable, and losses have increased over the past 5 years at a rate of 44.8% per year.
Accelerating Growth: Unable to compare AY20's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AY20 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.8%).
Return on Equity
High ROE: AY20 has a negative Return on Equity (-170.61%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/04/08 13:46 |
| End of Day Share Price | 2023/01/10 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Aytu BioPharma, Inc. is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jennifer Kim | Cantor Fitzgerald & Co. |
| Jeffrey Cohen | Ladenburg Thalmann & Company |
| Nazibur Rahman | Maxim Group |